Lab Relief
Executive Summary
Reference laboratories, which have suffered for most of the past decade from ever-declining reimbursement rates, had a welcome piece of good news this year--as of Jan. 1, Medicare reimbursement for many anatomic pathology processes is slated to increase. The increases vary by procedure, but some of the biggest categories--biopsies, for example--will rise by as much as 33% over the next three years. Reimbursement for Pap smears is doubling, although Medicare is responsible for only a small portion of pap smears. The reimbursement hike caused Dianon to restate its revenue projections for this fiscal year from a 30% increase to a 40% increase.
You may also be interested in...
Impath's Informatics Play
Impath's unorthodox step into the cancer information business has made it attractive to Wall Street, but will its vast, specialized databases allow it to reap benefits from pharmacogenetics? The real value to Impath of its databases resides in their ability to promote work on targeted therapeutics, whose use in patients will depend on critical markers. But targeted therapeutics are a controversial concept that requires pharma companies to make basic changes in the way they operate. There's no guarantee Impath can get the pay-off it wants from its new initiatives.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."
Need a specific report? 1000+ reports available
Buy Reports